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HAX-1 is ubiquitously expressed in murine and human tissues and seems to be predominantly localized to mitochondria, and to a lesser extent to the endoplasmic reticulum and nuclear membrane. Previous studies have disclosed homozygous mutations in the HAX1 gene in patients with the autosomal recessive form of severe congenital neutropenia or Kostmann disease, indicating a critical role for HAX-1 in the regulation of myeloid progenitor cell survival in the bone marrow.
2 More recent studies point to a critical role of HAX-1 in B-cell development, at least in mice.
3 HAX-1 was initially suggested to display homology with BCL-2, and several studies have implicated HAX-1 in the regulation of apoptosis.
HAX-1 may also have a role in cell migration, which in turn could have implications for the invasive activity and metastatic potential of cancer cells. 4 However, despite its ubiquitous expression and apparent roles in cell death and cell migration, very few studies have investigated the expression of HAX-1 in human tumors, 5 and the expression of HAX-1 in hematopoietic malignancies is unknown. Therefore, we studied the pattern of expression of HAX1 mRNA in human cancer using publically available transcriptomics databases. Gene expression profiling is a powerful strategy for improved understanding of the underlying pathogenesis and biology of lymphomas. Several studies have generated gene signatures that can classify and differentiate sub-groups of lymphomas and some signatures were also predictive for survival and treatment response. For instance, our previous study using transcriptomic profiling of a set of follicular lymphomas identified a six-gene profile that associated with favorable outcome and response to CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone).
6
The recent collection of large sets of public microarray data into databases has become a valuable tool for initial exploration of genes across thousands of samples of normal and cancer tissues. We determined the expression of HAX1 in two public transcriptomics databases, the in silico transcriptomics (IST) database that contains data from 9.783 Affymetrix gene expression analyses of 43 normal tissues, 68 cancer types and 64 other diseases, and the recently developed human gene expression map derived from 5.372 samples of 369 different cell and tissue types including various disease states. 7, 8 Using the IST database, we noted that HAX1 was highly expressed in particular in B-cell-related hematopoietic malignancies, including plasma-cell leukemia and B-cell lymphomas ( Figure 1a , and see Figure 2a for HAX1 expression in all tumor types). Interrogation of the human gene expression map, which includes 96 biological groups, showed that HAX1 was significantly overexpressed in hematological neoplasms such as anaplastic large cell lymphoma, as well as in breast ductal carcinoma (Figure 1b) . Furthermore, HAX1 expression was low in chronic myeloid leukemia and acute lymphoblastic leukemia (Figure 1a ). For comparison, we also assessed the expression of BCL2 in the two public transcriptomics databases (Figure 1a , for hematopoietic malignancies, and see Figures 1b and 2b for all tumor types, based on the IST and human gene expression map databases).
Next, we examined the expression of HAX-1 protein in a series of paraffin-embedded diagnostic samples from 50 patients with B-cell lymphoma (Table 1) ;14) translocation. The panel included six follicular (FC) lymphoma samples selected from a previously published cohort that we have studied using microarray gene expression profiling.
6 On the basis of the microarray data, we selected three samples with Each box contains at least 10 replicates and represents the quartile distribution (25-75%) range with the median indicated with a black vertical line. The 95% range including individual outlier samples is also displayed. The coloring of the boxes indicates the result from statistical testing for significantly increased (red) or decreased (blue) expression. The y-axis displays the relative gene expression levels (log2-transformed).
high expression and three with low expression of HAX1 mRNA for immunohistochemical studies. Biopsies of reactive tonsils and lymph nodes were used as controls. These studies were approved by the ethical committee at Karolinska Institutet.
In reactive lymphatic tissue, HAX-1 protein was expressed in B cells of germinal centers of BCL-2 negative, reactive follicles (Figure 3a) . HAX-1-positive immunoblasts were also present in the interfollicular zones (Figure 3b ). The HAX-1 antibody (BD Transduction Laboratories, Franklin Lakes, NJ, USA) detected cytoplasmic staining with a microgranular pattern consistent with the previously suggested mitochondrial localization of HAX-1. In FC lymphomas that normally overexpress BCL-2, we observed cases with high and low expression of HAX-1. One of the cases with high HAX-1 expression was negative for BCL-2. High expression of HAX-1 protein was found in all five cases of diffuse large B-cell lymphomas with germinal center cell-related phenotype (CD10 þ , Bcl-6 þ , MUM-1À). In three of these cases no BCL-2 expression was Letters to the Editor found in tumor cells (Figures 3c and d) . However, both HAX-1 and BCL-2 expression was noted in four cases of diffuse large B-cell lymphomas with activated B-cell phenotype (CD10À, MUM-1 þ ). All five tested cases of Burkitt's lymphoma showed a high HAX-1 expression and they were all BCL-2 negative (Figures 3e and f) . Most low-grade lymphomas usually show a high BCL-2 expression. In lymph-node samples from patients with B-cell chronic lymphatic leukemia, HAX-1 expression was associated with increased proliferation, as determined based on Ki67 staining (Figure 3g) . Small B-cell chronic lymphatic Figure 2 Box plot analysis of the gene expression levels of HAX1 (a) and BCL2 (b), in different human malignancies. The results were retrieved from the IST database, which contains data on 68 different cancer types.
7 Each box represents the quartile distribution (25-75%) range with the median indicated with a red vertical line. The 95% range including individual outlier samples is also displayed. Table 1 HAX-1 and BCL-2 protein expression in B-cell lymphoma Letters to the Editor leukemia cells were negative, whereas activated paraimmunoblasts in proliferation centers were positive for HAX-1. Strong positivity was found in a case of B-cell chronic lymphatic leukemia transformed to diffuse large B-cell lymphoma. Both tested cases of immunocytoma were negative for HAX-1 expression. In most cases of conventional mantle cell lymphoma and extranodal marginal cell mucosa-associated lymphoid tissue (MALT) lymphoma, only weak or no HAX-1 expression was detected. In classical Hodgkin's lymphoma, Reed-Sternberg and Hodgkin cells were HAX-1 positive (Figure 3h ). HAX-1 expression was also found in large 'popcorn-like' cells in nodular lymphocyte predominance Hodgkin's lymphoma. The semi-quantitative evaluation of HAX-1 and BCL-2 protein expression, and the proliferation assessment using Ki67 as a marker, is compiled in Table 1 . We then analyzed the relative transcript expression levels of HAX1 and BCL-2 in a previously published cohort of follicular lymphoma patients for which gene expression profiling was available. 6 As shown in Figure 4 , a negative correlation between HAX1 and BCL2 expression was evidenced at the mRNA level.
In conclusion, we provide an assessment of the pattern of HAX-1 expression at the protein and transcript level in different types of B-cell lymphoma. Our immunohistochemical data suggest that HAX-1 expression negatively correlates with BCL-2 expression in several forms of B-lymphoma and this finding was validated at the transcript level for follicular lymphoma. On the basis of this observation, one may speculate that HAX-1 functions as a 'functional' homolog of BCL-2 to compensate for low expression of BCL-2, at least in some tumors. On the other hand, the current data also point to a positive association between the proliferation marker Ki67 and HAX-1 expression, suggesting that HAX-1 may exert other functions not necessarily related to the suppression of apoptosis. Further studies are warranted to understand the functional relevance of elevated HAX-1 expression in human B lymphoma.
Conflict of interest
The authors declare no conflict of interest. 6 The transcript data were extracted from the microarray analysis of HAX1 and BCL2 using Affymetrix (Santa Clara, CA, USA) probes targeting directly to Ensembl gene IDs. To assess the association of these two genes the Pearson's correlation was calculated using the GraphPad Prism 5.03 software (La Jolla, CA, USA), and a P-value o0.05 was considered significant. (h) HAX-1 protein expression seen in Reed Sternberg cells of classical Hodgkin's lymphoma of mixed cellularity type. The protein expression of the HAX-1 protein was evaluated by immunohistochemistry using Bond-Max System (Leica, Newcastle Upon Tyne, UK). Slides were incubated with mouse anti-HAX-1 monoclonal antibody (BD Transduction Laboratories, Franklin Lakes, NJ, USA) or mouse anti-BCL-2 monoclonal antibody (Novocastra, Leica system, Newcastle Upon Tyne, UK). HAX-1 expression was evaluated semiquantitatively using expression observed in reactive germinal centers as positive control ( þ ). Samples with higher expression were scored as strong expression ( þ þ ). Similarly, BCL-2 expression was scored as positive if the staining corresponded to that of normal T-cells ( þ þ ). Samples overexpressing BCL-2 were scored as þ þ þ and weak expression was scored as þ . Diffuse large B-cell lymphomas samples were also stained with mouse anti-CD10 monoclonal antibody, mouse antiBcl-6 monoclonal antibody and mouse anti-MUM-1 monoclonal antibody (DakoCytomation, Glostrup, Denmark) to establish germinal center cell or activated B-cell phenotype. Proliferation was evaluated using Ki67 index after staining with mouse anti-Ki67 monoclonal antibody (DakoCytomation).
